AngioDynamics, Inc. (ANGO)

AngioDynamics' stock has experienced several notable events over the past six months, including a 29.64% increase in stock price and an 81.43% increase between October 10, 2024, and October 9, 2025. On October 2, 2025, AngioDynamics reported its Fiscal Year 2026 first-quarter financial results, announcing a 12.1% increase in revenue year-over-year, reaching $75.71 million, and adjusted its FY 2026 guidance. Canaccord Genuity Group raised its price target for AngioDynamics on October 3, 2025, while Wall Street Zen downgraded the stock rating on October 4, 2025. Weiss Ratings reaffirmed a "sell" rating on October 8, 2025. CEO James C. Clemmer purchased 10,000 shares on October 9, 2025, while Representative Debbie Wasserman Schultz sold stock on October 20, 2025. SVP Lawrence T. Weiss purchased 10,000 shares on October 21, 2025. AngioDynamics announced its participation in the UBS Global Healthcare Conference on November 10, 2025, and provided an update on the ongoing clinical study for the AlphaVac System on October 27, 2025.

AngioDynamics experiences some demand seasonality, with cash utilization typically highest in its first fiscal quarter and significant cash generation expected in the fourth fiscal quarter.

AngioDynamics, Inc. is a medical technology company focused on developing minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology and surgical settings. The company's business is focused on developing transformative medical solutions to restore healthy blood flow, expand cancer treatment options, and improve patient quality of life. Its major products are categorized into Med Tech and Med Device segments. The Med Tech segment includes advanced technology platforms such as the Auryon Atherectomy system, the AlphaVac and AngioVac mechanical thrombectomy systems, and the NanoKnife System. The Med Device segment encompasses core, venous, ports, and other oncology products, including BioFlo PICCs and Ports, hemodialysis catheters, specialty blood management products, angiographic and drainage products, and the VenaCure EVLT system. The company also offers the Solero Microwave Tissue Ablation System.

AngioDynamics has a global presence with operations in the United States and internationally. Its global headquarters are in Latham, New York, with additional manufacturing facilities in Glens Falls and Queensbury, New York, and an office in Massachusetts. Internationally, the company has offices in Canada, Hong Kong, The Netherlands, Israel, and Brazil, and subsidiaries in France and the United Kingdom.

AngioDynamics received positive recognition with its NanoKnife® System being named to TIME's 2025 Best Inventions List.

AngioDynamics' ownership is primarily institutional, with these investors holding 74% of the company's shares. Major institutional shareholders include BlackRock, Inc., Divisadero Street Capital Management, LP, Systematic Financial Management Lp, Vanguard Group Inc, Point72 Asset Management, L.P., Armistice Capital, Llc, Millennium Management Llc, Segall Bryant & Hamill, Llc, and Dimensional Fund Advisors Lp. Howard S. Stern, one of the company's founders, is the largest individual shareholder, owning 4.00% of the company's shares, while CEO James Clemmer directly holds 1.2% of the total shares outstanding.